Palisade Bio Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Palisade Bio is de winst gegroeid met een gemiddeld jaarlijks percentage van 6%, terwijl de Pharmaceuticals industrie de winst jaarlijks groeide met 12.9%. De inkomsten zijn gegroeid met een gemiddelde van 99.9% per jaar.

Belangrijke informatie

6.0%

Groei van de winst

25.7%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	7.3%
Inkomstengroei	99.9%
Rendement op eigen vermogen	-134.0%
Nettomarge	n/a
Laatste winstupdate	31 Mar 2024

Recente prestatie-updates uit het verleden

Geen updates

Recent updates

Opbrengsten en kosten

Hoe Palisade Bio geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

DB:7NS0 Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
31 Mar 24	0	-14	6	8
31 Dec 23	0	-12	6	7
30 Sep 23	0	-13	6	8
30 Jun 23	0	-14	7	8
31 Mar 23	0	-13	7	7
31 Dec 22	0	-15	9	7
30 Sep 22	0	-9	10	5
30 Jun 22	0	0	11	4
31 Mar 22	0	-27	11	3
31 Dec 21	0	-27	9	2
30 Sep 21	0	-32	9	2
30 Jun 21	0	-39	8	2
31 Mar 21	0	-12	6	3
31 Dec 20	0	-10	6	3
30 Sep 20	0	-9	6	3
31 Dec 19	0	-10	7	3
31 Dec 18	1	-4	4	1

Kwaliteitswinsten: 7NS0 is momenteel verliesgevend.

Groeiende winstmarge: 7NS0 is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: 7NS0 is verlieslatend, maar heeft de verliezen de afgelopen 5 jaar met een snelheid van 6% per jaar verminderd.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van 7NS0 over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: 7NS0 is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Pharmaceuticals industrie ( 28.7% ).

Rendement op eigen vermogen

Hoge ROE: 7NS0 heeft een negatief Return on Equity ( -134.01% ), omdat het momenteel verliesgevend is.

Palisade Bio Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Recent updates

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis

Palisade Bio Announces First Subject Dosed in Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis (UC)

Palisade Bio, Inc. Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio, Inc. has filed a Follow-on Equity Offering.

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could Be Utilized as a Potential Marker for Patient Stratification

Palisade Bio, Inc. Selects Dose for Upcoming Phase 1 Clinical Study of PALI-2108 for Ulcerative Colitis

Palisade Bio, Inc. Successfully Completes Microbiome Study Confirming Bacterial Enzymes for Local Bioactivation of Leading Product Candidate, PALI-2108

Palisade Bio, Inc. Announces Successful Completion of First GMP Manufacturing of PALI-2108 Drug Substance and Engineering Batches of Drug Product

Palisade Bio, Inc., Annual General Meeting, Jul 08, 2024

Palisade Bio, Inc. Announces Presentation of Positive Preclinical Data from PALI-2108

Palisade Bio, Inc. announced that it has received $3.999943 million in funding

Palisade Bio, Inc. Appoints Margery Fischbein to Its Board of Directors

Palisade Bio, Inc. announced that it expects to receive $3.999996 million in funding

Palisade Bio’s Lead Product Candidate, PALI-2108 Demonstrates Potent Anti-Inflammatory Effects in Ex-Vivo Study of Whole Blood Samples Challenged with Pro-Inflammatory Lipopolysaccharide (LPS)

Palisade Bio Successfully Demonstrates Bioactivation of PALI-2108 In Ex-Vivo Study of Normal Healthy and Ulcerative Colitis Patients’ Stool

Palisade Bio, Inc. Receives Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC Regarding Non-Compliance with the Audit Committee Requirements

Palisade Bio, Inc. Announces Advisory Board Appointments

New major risk - Share price stability

Palisade Bio, Inc. has withdrawn its Follow-on Equity Offering in the amount of $5 million.

Palisade Bio, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Palisade Bio, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

New major risk - Revenue and earnings growth

Palisade Bio Receives Non-Compliance Notice from Nasdaq

Palisade Bio, Inc. has completed a Follow-on Equity Offering in the amount of $1.965094 million.

Palisade Bio, Inc. has completed a Follow-on Equity Offering in the amount of $1.965094 million.

New major risk - Market cap size

Palisade Bio, Inc. Announces Topline Results from U.S. Phase 2 Profile Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions

Palisade Bio, Inc. Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study

Palisade Bio, Inc. Announces Board Appointments

Palisade Bio, Inc. has completed a Follow-on Equity Offering in the amount of $1.220371 million.

Palisade Bio, Inc. announced that it has received funding

Palisade Bio Regains Compliance with Nasdaq Listing Requirements

U.S. Food and Drug Administration Grants Fast Track Designation to Palisade Bio for LB1148 for Accelerated Return of Bowel Function Following GI Surgery

Palisade Bio Appoints Herbert B. Slade MD, FAAAAI as Chief Medical Officer

Palisade Bio, Inc. Terminates Michael Dawson as Chief Medical Officer

Palisade Bio, Inc. Announces Executive Changes

Palisade Bio, Inc. Announces Chief Executive Officer Transition

Palisade Bio Announces Oral Presentation of Phase 2 Data at the American College of Surgeons Clinical Congress 2022

Palisade Bio, Inc. Announces the Commencement of Patient Enrollment and Dosing in Its Pivotal Phase 3 Study Evaluating LB1148

Palisade Bio Announces First Patient Enrolled and Dosed in Pivotal Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

Palisade Bio, Inc. has completed a Composite Units Offering in the amount of $12 million.

Palisade Bio, Inc. Announces First Patient Screened in Phase 3 Study Evaluating LB1148 for Postoperative Return of Bowel Function

Palisade Bio Initiates Phase 3 Study of Lb1148 in Lead Indication for Postoperative Return of Bowel Function

Palisade Bio, Inc. Receives Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard

Palisade Bio, Inc. announced a financing transaction

Palisade Bio, Inc. and Newsoara Biopharma Co., Ltd. Receives NMPA Clearance to Commence Phase 3 Clinical Trial in China Evaluating LB1148

High number of new directors

Palisade Bio, Inc., Annual General Meeting, Jun 09, 2022

Palisade Bio, Inc. Appoints Robert McRae as Senior Vice President, Operations and Strategic Development

Palisade Bio to Announce Adhesions Clinical Data at SAGES 2022 Annual Meeting

High number of new and inexperienced directors

Palisade Bio, Inc. announced that it has received $5.209141 million in funding from Yuma Regional Medical Center

Palisade Bio, Inc. announced delayed 10-Q filing

Palisade Bio Receives FDA Fast Track Designation for LB1148 for Reduction of Adhesions Following Abdominal and Pelvic Surgery

Palisade Bio and Newsoara Announce Completion of Phase 2 Study in GI Surgery Study in China

Opbrengsten en kosten

Inkomsten en omzetgeschiedenis

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Rendement op eigen vermogen

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden